David A. Siegel Regeneron Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 553,800 shares of REGN stock, worth $272 Million. This represents 0.82% of its overall portfolio holdings.
Number of Shares
553,800Holding current value
$272 Million% of portfolio
0.82%Shares
26 transactions
Others Institutions Holding REGN
# of Institutions
1,471Shares Held
85.8MCall Options Held
1.39MPut Options Held
1.45M-
Vanguard Group Inc Valley Forge, PA9.41MShares$4.61 Billion0.11% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$4.14 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY5.66MShares$2.77 Billion0.28% of portfolio
-
State Street Corp Boston, MA4.79MShares$2.35 Billion0.13% of portfolio
-
Capital International Investors Los Angeles, CA3.99MShares$1.96 Billion0.52% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $52.6B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...